Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of subcutaneously administered teplizumab in adults with relatively recent onset T1DM, greater than 12 weeks and less than 52 weeks of presentation of first signs and symptoms of disease to a physician prior to randomization.

Timeline

Start

2010-08

Primary completion

2011-02

Completion

2011-02

Drugs

Indications